VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)

Inclusion Criteria:

• Age >18; <65 yo
• Previous diagnosis of SARS-CoV-2 infection, documented by nasopharyngeal or antigenicmolecular swab;
• Not currently be in quarantine or isolation;
• No antibiotics treatment in the 30 days prior to the trial;
• Chalder Fatigue Scale (in dichotomous form)>=4 possibly associated with signs andsymptoms of Long COVID-19 syndrome: signs and symptoms that develop during or afterSARS-CoV-2 infection, which persist for more than 4 weeks and are not reasonablyexplained otherwise; signs and symptoms include: fatigue, sleep disturbances,cognitive deficits (i.e. brain fogging, loss of concentration and memory, anxiety,depression), strength deficits, arthralgias and myalgias, gastroenterologicalalterations (reduced appetite, nausea, changes in bowel habits, abdominal pain

Exclusion Criteria:

• Cardiovascular and pulmonary disease with moderately severe organ dysfunction (NYHA>2,Borg scale>=2);
• Decompensated endocrine and metabolic diseases (child cirrhosis >= B, decompensatedhypo/hyperthyroidism, decompensated hypoadrenalism)
• Diagnosis of FM, CFS/ME, and/or IBS prior to SARS-CoV-2 infection;
• Confirmed diagnoses of neurological pathologies, psychiatric diseases and cognitivedisorders prior to SARS-CoV-2 infection;
• Previous confirmed diagnosis of chronic musculoskeletal pathologies prior to prior toSARS-CoV-2 infection;
• Refusal to participate in the study / refusal to process personal data;
• Pregnancy or breastfeeding;
• Addiction to alcohol or drugs in previous years;
• Use of other probiotics during the trial;
• Use of antibiotics during the trial and in the previous 30 days;
• Substantial change of diet during the trial;
• Participation in another clinical study in the previous 30 days or previousparticipation in this same trial;
• Known intolerance/hypersensitivity to the investigational drug or to the excipients ofthe placebo formulation